LEO Pharma’s Adbry (tralokinumab-ldrm) Autoinjector Receives the US FDA’s Approval to Treat Moderate-to-Severe Atopic Dermatitis (AD)
Shots:
- The US FDA has approved Adbry (tralokinumab-ldrm) 300mg/2mL single-dose autoinjector for adults with moderate-to-severe atopic dermatitis. It was already approved for participants aged ≥12yrs.
- Adbry was previously approved as 1mL pre-filled syringe and now with 300mg/2mL autoinjector, patients can now be treated with half the no. of injections vs the prior ones (150mg/1mL)
- The single-dose autoinjector marks another method of administration and its availability is anticipated in the H2’24
Ref: Bussinesswire | Image: LEO Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
